Wegovy Weight Loss Injection UK: Complete Patient Guide

If you are considering Wegovy for weight loss, you are likely looking for clear, factual information — not hype, pressure, or unrealistic promises.

This guide is the complete UK patient reference for Wegovy. It covers what the medication is, how it works mechanistically, who is and isn’t clinically suitable, the full dose schedule, what the STEP-1 trial data shows about realistic outcomes, side effects and management, costs, NHS vs private access, and the practical aspects of treatment (injection technique, storage, missed doses).

Wherever you can go deeper, this guide links to a focused supporting article — so you can read the overview here and then explore the detail at your own pace.

What Is Wegovy?

Wegovy is a once-weekly prescription injection used to support weight loss in adults with overweight or obesity. It contains semaglutide, a synthetic version of a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), and is manufactured by Novo Nordisk.

Key facts about Wegovy:

• Active ingredient: Semaglutide
• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• UK regulatory approval: MHRA-licensed since 2021; available in UK from September 2023
• NICE recommendation: Technology Appraisal TA875 (March 2023)
• Administration: Subcutaneous injection, once weekly
• Dose range: 0.25mg starter to 2.4mg maintenance
• Pivotal trial: STEP-1 (Wilding et al., NEJM 2021)

Wegovy is not a diet replacement or a quick fix. It is a medical treatment designed to work alongside a reduced-calorie diet and increased physical activity, not instead of them — this is how it was studied in clinical trials and how it is licensed in the UK.

How Wegovy Works in the Body

Wegovy mimics GLP-1, a hormone released by the gut after eating that plays multiple roles in appetite regulation and digestion. By activating GLP-1 receptors, Wegovy produces several effects:

• Slows gastric emptying — food stays in the stomach longer, producing sustained fullness
• Reduces appetite signals — hunger feels less constant and less intense
• Increases satiety — meals feel satisfying sooner
• Reduces food noise — the constant mental occupation with food softens for many patients
• Modulates reward responses to food — cravings for high-calorie foods reduce
• Improves blood sugar control — stimulates appropriate insulin release

The combined effect is that patients eat less without feeling deprived, and the reduction in calorie intake — sustained over many months — produces meaningful weight loss.

Semaglutide has a half-life of approximately 7 days, which is why Wegovy is dosed weekly. This long half-life also produces more steady appetite control than shorter-acting GLP-1 medications like Saxenda (liraglutide, dosed daily).

Who Is Wegovy Suitable For?

Eligibility for Wegovy follows NHS and NICE-informed clinical guidance, whether treatment is accessed publicly or privately. Eligibility is always assessed individually through a medical consultation.

Standard private prescribing criteria

You may be considered clinically suitable for Wegovy if:

• BMI of 30 or above (obesity), or
• BMI of 27 or above with at least one weight-related health condition, such as:
  • Type 2 diabetes
  • High blood pressure (hypertension)
  • Dyslipidaemia (high cholesterol or triglycerides)
  • Cardiovascular disease
  • Obstructive sleep apnoea
  • Polycystic ovary syndrome (PCOS)
  • Non-alcoholic fatty liver disease
  • Osteoarthritis affecting weight-bearing joints

Additional clinical factors

• You are 18 years or older
• You have tried lifestyle approaches without sufficient sustained weight loss
• You can commit to a reduced-calorie diet and increased physical activity
• You can attend follow-up clinical reviews
• You have no contraindications (see next section)

If you are also considering Mounjaro: Mounjaro UK eligibility 2026.

Who Should Not Take Wegovy

Wegovy is contraindicated — meaning it should not be used — in several specific groups. A proper clinical consultation will screen for these.

Wegovy requires individualised clinical assessment in patients with:

• History of acute pancreatitis
• History of gallstones or gallbladder disease
• Severe kidney or liver disease
• Type 2 diabetes with diabetic retinopathy
• Concurrent use of insulin or sulphonylureas (hypoglycaemia risk)
• Other medications affected by delayed gastric emptying

Wegovy on the NHS vs Private Access

Wegovy is available on the NHS in England under NICE Technology Appraisal TA875, but access is significantly restricted.

NHS access (NICE TA875)

• Available only through Tier 3 specialist weight management services
• Typically requires BMI ≥35 with at least one weight-related comorbidity
• Often requires a GP referral to specialist services
• Long waiting lists in many regions
• Maximum 2 years of treatment under the NICE recommendation
• Limited capacity means most clinically eligible patients still access privately

Private access

• Faster assessment — typically within 24 hours at Slinic
• No GP referral needed
• More personalised dose progression
• Ongoing review and support included
• No artificial 2-year cap on treatment duration
• Continuity of care with a named prescriber

Importantly, private care must still meet the same UK safety and prescribing standards as NHS treatment — the clinical floor is identical. What differs is access speed and treatment flexibility.

Wegovy Dose Schedule

Wegovy treatment starts at a low 0.25mg dose and increases gradually to help your body adjust and reduce side effects. The MHRA-approved schedule is:

Early doses are not designed for weight loss — they support comfort and tolerability. Most weight loss happens at the 1mg dose and onwards, with the steepest loss typically occurring between weeks 16 and 40 on the maintenance dose.

Dose progression is personalised: prescribers can extend a particular dose if you are still adjusting, slow the schedule, or in some cases hold at a lower dose if appetite control is sufficient.

For the full breakdown of what each dose feels like and how progression works: Wegovy dosages explained 0.25mg to 2.4mg.

Weight Loss Outcomes: What the STEP-1 Trial Shows

The pivotal STEP-1 clinical trial (Wilding et al., NEJM 2021) enrolled 1,961 adults with obesity over 68 weeks. The results define what realistic Wegovy outcomes look like.

Average weight loss timeline

Response rates at week 68

• 86% of patients achieved ≥5% weight loss
• 69% achieved ≥10% weight loss
• 50% achieved ≥15% weight loss
• 32% achieved ≥20% weight loss

The clinical response benchmark is ≥5% weight loss by 12 weeks at the maintenance dose. Most patients exceed this. Patients who do not may benefit from extended titration, lifestyle review, or considering Mounjaro (tirzepatide), which has produced stronger outcomes in head-to-head data.

For detailed timelines including kg expectations by starting weight: How fast can you lose weight on Wegovy?

Common Side Effects (and What’s Normal)

Some patients experience side effects, particularly early in treatment or during dose increases. Most are mild to moderate and improve as the body adjusts.

From the STEP-1 trial:

• Nausea (~44%) — most common, peaks early and around dose increases
• Diarrhoea (~32%)
• Vomiting (~24%)
• Constipation (~24%)
• Abdominal pain (~20%)
• Headache (~14%)
• Fatigue (~11%)
• Indigestion / reflux (~5-9%)
• Injection site reactions (~3%) — usually minor

Discontinuation due to side effects was uncommon in STEP-1 (~4.5%). Most patients who experience side effects can continue treatment with adjusted dose pacing or practical management strategies.

For detailed management strategies: Wegovy side effects and how to manage them.

How to Inject Wegovy

Wegovy is delivered via a pre-filled, single-use Novo Nordisk FlexTouch pen — a subcutaneous (under-the-skin) injection given once weekly on the same day each week.

Where to inject

• Front of the thigh — easiest for most patients
• Abdomen — at least 5cm away from the navel
• Upper arm — usually only practical with help

Best practice

• Rotate injection sites each week to reduce irritation
• Clean the skin with an alcohol wipe and let it dry
• Pinch the skin gently to lift it
• Hold the pen firmly against the skin at 90 degrees
• Press and hold the dose button until the marking shows 0, then count to 6 before removing
• Dispose of pens in a sharps bin — never household waste

Your prescribing pharmacist can walk you through technique on your first dose. Most patients find the second injection feels routine.

Storage and Missed Doses

Storage instructions

• Before first use: Store refrigerated at 2-8°C — keep in the original carton, protected from light
• After first use: The pen can be stored either in the fridge (2-8°C) or at room temperature (up to 30°C)
• Room temperature window: A pen kept at room temperature must be used within 6 weeks of first use
• Never freeze — discard any pen that has been frozen
• Keep out of reach of children

What to do if you miss a dose

If you miss multiple consecutive doses (2 or more), contact your prescriber. Tolerance can reduce after a gap, and your dose may need to be lowered temporarily before stepping back up.

What Eating Feels Like on Wegovy

Most patients describe a meaningful shift in their relationship with food. Common experiences:

• Portions naturally feel smaller
• Cravings reduce — particularly for sweet and high-fat foods
• Heavy or rich meals feel less appealing
• “Food noise” — the constant mental occupation with food — quietens significantly
• Snacking between meals decreases or stops naturally
• Fullness signals feel reliable rather than aspirational

This is why simple, balanced meals and listening to hunger cues tend to work well during treatment. Trying to force normal-sized meals when fullness arrives early often worsens nausea.

Eating well on Wegovy

• Prioritise protein (1.2-1.6g per kg body weight) to preserve muscle
• Stay hydrated — at least 1.5-2 litres of fluid daily
• Eat slowly — your fullness signals will arrive sooner than they did before
• Avoid very greasy, spicy, or rich foods early in treatment
• Don’t skip meals — small frequent meals work better than waiting until hungry

How Much Wegovy Costs

Slinic publishes Wegovy pricing transparently across the full dose ladder. There are no separate consultation fees, follow-up charges, or delivery costs.

A full first year of treatment at Slinic — through the 16-week titration plus 8 months at 2.4mg maintenance — costs approximately £2,164.88. Subsequent years at the maintenance dose cost approximately £2,519.88.

Across the wider UK private market, prices vary significantly — starter doses range £125-£195+, maintenance doses range £225-£330+, and some providers charge consultation fees on top of medication prices.

For full pricing detail including the UK market comparison: Wegovy cost UK 2026: private prescription prices explained.

Wegovy vs Other Weight Loss Treatments

Wegovy vs Mounjaro (tirzepatide)

Mounjaro is a dual GIP/GLP-1 receptor agonist — a different class of medication that has produced the strongest weight loss outcomes in trials. In the SURMOUNT-1 trial, Mounjaro produced ~22.5% average weight loss at the 15mg dose. The SURMOUNT-5 head-to-head trial showed tirzepatide outperformed semaglutide directly. For patients without specific contraindications, Mounjaro is now often the first-line choice based on outcomes alone.

Full comparison: Mounjaro vs Wegovy.

Wegovy vs Saxenda (liraglutide)

Saxenda is also a GLP-1 receptor agonist but is shorter-acting (daily injection) and was the earlier generation. The STEP 8 head-to-head trial (JAMA 2022) showed Wegovy produced ~15.8% weight loss vs ~6.4% for Saxenda over 68 weeks. Most patients now choose Wegovy unless there’s a specific reason for daily dosing.

Full comparison: Wegovy vs Saxenda.

Clinician-Led Care at Slinic

At Slinic, Wegovy is prescribed as part of a clinician-led, safety-first approach. All prescriptions are reviewed by UK-registered prescribers, dispensed by a GPhC-regulated pharmacy, issued only after full medical assessment, and supported by ongoing pharmacist-led review.

Shadeia Younis

Superintendent Pharmacist, Slinic (GPhC 2052119)

Every Wegovy prescription dispensed by Slinic is clinically verified by Shadeia Younis, our superintendent pharmacist. That means before your medication leaves the pharmacy it has been checked by a qualified, registered professional accountable for its safety under UK law.

Patients have access to pharmacist-led clinical support throughout treatment — not just at the initial consultation. Dose-change questions, side effect concerns, and clinical guidance are part of the monthly service rather than separate paid follow-ups.

GPhC Registered Pharmacist GPhC No. 2052119 Superintendent Pharmacist, GPhC Pharmacy 1033729 Specialist in Weight Loss Treatment

Related Wegovy Guides From Slinic

This is the central Wegovy hub. The guides below go deeper on each aspect of treatment.

Frequently Asked Questions

Medical Disclaimer

This article provides comprehensive educational information about Wegovy (semaglutide) for UK patients and is not a substitute for professional medical advice. Wegovy is a prescription-only medicine and should only be used together with a reduced-calorie diet and increased physical activity under appropriate clinical supervision. Always consult qualified healthcare providers before starting weight loss medication. Individual results vary substantially from trial averages. Prices correct as of April 2026 and may be subject to change.